Category Archives: Events

Latest From Events

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

DSC_8551

The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and Beyond

electroceuticals panel

Some of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee the day of diminishing returns from research in traditional molecular biology?” These researchers are investigating alternative modalities of providing therapy that would combine electronic sensing with drug delivery or even stimulating the body through electricity alone to produce a desired response. These “electroceutical,” or “bioelectronics,” approaches have produced exciting results in early clinical trials, particularly related to insulin control and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

Biotech IPOs Infographic

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Ken Drazan, MD

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, who serves as the head of Johnson & Johnson Innovation in California. The conversation was moderated by Deepa R. Pakianathan, PhD, a general partner for Delphi Ventures who leads the firm’s biotechnology investment activities. Ken Drazan has a unique viewpoint which results from having experience with both the biopharma start-up world as well as in the investment community. This background Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

BIO Investor Forum

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming the body’s own t-cells to have greater impact on reducing tumors and preventing the spread of disease. CAR-T methods that extract, reengineer, and reintroduce a given patient’s t-cells provide highly personalized therapy but may be difficult to scale up. The interleukin enhancement approach motivates existing t-cells to be more effective and may be easier to deliver but have less pervasive Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,